Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
Status:
Completed
Trial end date:
2001-06-01
Target enrollment:
Participant gender:
Summary
To demonstrate the effect of JTT-705 doses from 300 mg to 900 mg on the elevation of HDL-C
and on the inhibition of CETP activity versus placebo, in patients presenting with mild
dyslipidaemia. These objectives will be tested after 4 weeks of treatment.